NEW YORK, Feb. 26 – Xerion Pharmaceuticals has acquired exclusive rights to cancer targets identified by a Tufts University scientist, the company said today.

The Martinsried, Germany-based firm, in a statement, said it will use the targets to create therapeutic antibodies. The targets were identified in the lab of Daniel Jay, a professor of physiology at Tufts.

Financial details of the agreement were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.